Research
Hormonal
Specialist clinicians have historically approached cardiovascular, kidney, and metabolic disorders as separate diseases.
Clinicians may need to reconsider their treatment strategies to integrate care for CKM syndrome.
StrongSupportsmedium confidence
Specialist clinicians have historically approached these disorders as separate diseases, with individual treatment plans specific to dysfunction of each organ system.
Why this rating
The claim is based on established clinical practices.
Source
The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Cardiovascular-Kidney-Metabolic Syndrome
Sonal Kumar et al. · JACC Advances · 2026
DOI 10.1016/j.jacadv.2025.102465
reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →